601.71 USD
+2.5 (+0.42%)
Taking everything into account, MEDP scores 7 out of 10 in our fundamental rating. MEDP was compared to 57 industry peers in the Life Sciences Tools & Services industry. MEDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDP is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes MEDP very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
MEDP had positive earnings in the past year.
In the past year MEDP had a positive cash flow from operations.
Each year in the past 5 years MEDP has been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of MEDP (24.70%) is better than 100.00% of its industry peers.
The Return On Equity of MEDP (147.46%) is better than 100.00% of its industry peers.
MEDP has a Return On Invested Capital of 91.45%. This is amongst the best in the industry. MEDP outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 13.75%.
The last Return On Invested Capital (91.45%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
The Profit Margin of MEDP (18.36%) is better than 92.98% of its industry peers.
In the last couple of years the Profit Margin of MEDP has grown nicely.
With an excellent Operating Margin value of 21.50%, MEDP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
In the last couple of years the Operating Margin of MEDP has grown nicely.
Looking at the Gross Margin, with a value of 31.11%, MEDP is doing worse than 70.18% of the companies in the same industry.
MEDP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
Compared to 1 year ago, MEDP has less shares outstanding
The number of shares outstanding for MEDP has been reduced compared to 5 years ago.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.39 indicates that MEDP is not in any danger for bankruptcy at the moment.
MEDP's Altman-Z score of 8.39 is amongst the best of the industry. MEDP outperforms 87.72% of its industry peers.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.39 |
ROIC/WACC8.35
WACC10.95%
2.3 Liquidity
A Current Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.57, MEDP is doing worse than 94.74% of the companies in the same industry.
A Quick Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
MEDP has a worse Quick ratio (0.57) than 92.98% of its industry peers.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.22% over the past year.
MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 33.22% yearly.
Looking at the last year, MEDP shows a quite strong growth in Revenue. The Revenue has grown by 13.88% in the last year.
MEDP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.62% yearly.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
The Earnings Per Share is expected to grow by 12.31% on average over the next years. This is quite good.
MEDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.31% yearly.
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 42.08, MEDP can be considered very expensive at the moment.
MEDP's Price/Earnings ratio is in line with the industry average.
MEDP's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.25.
Based on the Price/Forward Earnings ratio of 35.79, the valuation of MEDP can be described as expensive.
63.16% of the companies in the same industry are more expensive than MEDP, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of MEDP to the average of the S&P500 Index (23.98), we can say MEDP is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.08 | ||
| Fwd PE | 35.79 |
4.2 Price Multiples
MEDP's Enterprise Value to EBITDA ratio is in line with the industry average.
Based on the Price/Free Cash Flow ratio, MEDP is valued cheaply inside the industry as 80.70% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.05 | ||
| EV/EBITDA | 30.99 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of MEDP may justify a higher PE ratio.
A more expensive valuation may be justified as MEDP's earnings are expected to grow with 13.97% in the coming years.
PEG (NY)2.16
PEG (5Y)1.27
EPS Next 2Y15.37%
EPS Next 3Y13.97%
5. Dividend
5.1 Amount
MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:MEDP (1/13/2026, 10:35:43 AM)
601.71
+2.5 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.1%
Inst Owner Change0.55%
Ins Owners0.44%
Ins Owner Change-6.92%
Market Cap16.95B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target550.48 (-8.51%)
Short Float %6.34%
Short Ratio5.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)0.62%
PT rev (3m)27.09%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)11.42%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)5.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)1.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.08 | ||
| Fwd PE | 35.79 | ||
| P/S | 7.19 | ||
| P/FCF | 25.05 | ||
| P/OCF | 23.83 | ||
| P/B | 57.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.99 |
EPS(TTM)14.3
EY2.38%
EPS(NY)16.81
Fwd EY2.79%
FCF(TTM)24.02
FCFY3.99%
OCF(TTM)25.25
OCFY4.2%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.16
PEG (5Y)1.27
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 8.39 |
F-Score8
WACC10.95%
ROIC/WACC8.35
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.34%
EBIT Next 3Y15.87%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
Can you provide the valuation status for MEDPACE HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
What is the profitability of MEDP stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?
The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 42.08 and the Price/Book (PB) ratio is 57.72.
How financially healthy is MEDPACE HOLDINGS INC?
The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.